You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

H2 receptor antagonist

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma Trial in

Not yet recruiting
  • Anatomic Stage II Breast Cancer AJCC v8
  • +3 more
  • Biospecimen Collection
  • +7 more
  • Portland, Oregon
    SWOG
Sep 27, 2023

Chronic Pain Trial in Berlin (MEDI0618, Placebo)

Recruiting
  • Chronic Pain
  • Berlin, Germany
    Research Site
Jan 26, 2023

Carcinoma, Non-small-Cell Lung Trial in New York, Fairfax (JNJ-86974680, Cetrelimab, Radiation Therapy)

Recruiting
  • Carcinoma, Non-small-Cell Lung
  • New York, New York
  • +1 more
Nov 8, 2023

Breast Carcinoma, Estrogen Receptor Positive Trial in Palo Alto (drug, procedure, device)

Suspended
  • Breast Carcinoma
  • Estrogen Receptor Positive
  • Gallium Ga 68-labeled GRPR Antagonist BAY86-7548
  • +3 more
  • Palo Alto, California
    Stanford Cancer Institute Palo Alto
Dec 8, 2021

Chronic Urticaria Trial in Suwon-si

Completed
  • Chronic Urticaria
    • Suwon-si, Korea, Republic of
      Ajou University Medical Hospital
    Jul 4, 2019

    Breast Cancer, Breast Tumor Trial in Philadelphia ([18F]ISO-1)

    Active, not recruiting
    • Breast Cancer
    • Breast Neoplasm
    • Philadelphia, Pennsylvania
      University of Pennsylvania Hospital
    Jan 17, 2023

    Diffuse Midline Glioma (DMG), Glioblastoma, Recurrent Ependymoma Trial in San Francisco, Ann Arbor, Zürich (ONC206, Standard of

    Recruiting
    • Diffuse Midline Glioma (DMG)
    • +7 more
    • ONC206
    • Standard of Care Radiation Therapy
    • San Francisco, California
    • +2 more
    Sep 13, 2022

    Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Stage III Prostate Cancer AJCC v8 Trial in Seattle (drug,

    Not yet recruiting
    • Prostate Carcinoma
    • +3 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Oct 17, 2023

    COVID-19 Pneumonia Trial in Szczecin (Canrenoate Potassium, Normal Saline)

    Recruiting
    • COVID-19 Pneumonia
    • Canrenoate Potassium
    • Normal Saline
    • Szczecin, Poland
      Pomeranian Medical University
    Jun 3, 2021

    Diabetic Kidney Disease Trial in Australia (SER150, Placebo)

    Recruiting
    • Diabetic Kidney Disease
    • Liverpool, New South Wales, Australia
    • +6 more
    May 17, 2022

    Advanced Glioma, Complication of Chimeric Antigen Receptor (CAR-T) Cell Therapy Trial in Suzhou (Targeted IL-13 Ra2 UCAR-T cell

    Recruiting
    • Advanced Glioma
    • Complication of Chimeric Antigen Receptor (CAR-T) Cell Therapy
    • Targeted IL-13 Rα2 UCAR-T cell injection
    • Targeted B7-H3 UCAR-T cell injection
    • Suzhou, Jiangsu, China
      The Second Affiliated Hospital of Soochow University
    Mar 2, 2023

    Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma Trial in Boston,

    Active, not recruiting
    • Estrogen Receptor-positive Breast Cancer
    • +5 more
    • PI3K inhibitor BYL719
    • +3 more
    • Boston, Massachusetts
    • +1 more
    Oct 14, 2022

    Cardiovascular Drugs Adverse Reaction

    Recruiting
    • Pharmacogenetics
    • +2 more
    • Oral Anticoagulant, Direct-Acting
    • Zagreb, Croatia
      UHC Zagreb
    Mar 23, 2022

    Malignant Solid Tumor Trial in Nashville (Ifetroban Sodium, Placebo)

    Recruiting
    • Malignant Solid Tumor
    • Ifetroban Sodium
    • Placebo
    • Nashville, Tennessee
      Vanderbilt-Ingram Cancer Center
    Jun 23, 2022

    Diffuse Midline Glioma, H3 K27M-Mutant Trial (GD2 CAR T cells)

    Not yet recruiting
    • Diffuse Midline Glioma, H3 K27M-Mutant
    • GD2 CAR T cells
    • (no location specified)
    Sep 15, 2022

    Platinum-Resistant Ovarian Carcinoma Trial in Duarte (Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine)

    Recruiting
    • Platinum-Resistant Ovarian Carcinoma
    • Chimeric Antigen Receptor T-cells
    • +2 more
    • Duarte, California
      City of Hope Medical Center
    Jul 21, 2022

    Colorectal Cancer, Hematologic Malignancy, Rectum Cancer Trial in Cleveland (Vactosertib, Fludarabine Phosphate,

    Recruiting
    • Colorectal Cancer
    • +11 more
    • Cleveland, Ohio
      University Hospitals Cleveland Medical Center, Case Comprehensiv
    Jan 18, 2023

    Type 2 Diabetes, Obesity Trial in Sherbrooke (drug, other, diagnostic test, procedure)

    Recruiting
    • Type 2 Diabetes
    • Obesity
    • Formoterol Fumarate 12 micrograms Inhalation Powder
    • +8 more
    • Sherbrooke, Quebec, Canada
      Centre de recherche du CHUS
    Sep 22, 2022

    PONV in Laparoscopic Cholocystectomies Trial in Larissa (Dimenhydrinate Tablets, Ondansetron iv)

    Completed
    • PONV in Laparoscopic Cholocystectomies
    • Dimenhydrinate Tablets
    • Ondansetron iv
    • Larissa, Thessaly, Greece
      University Hospital of Larisa, Department of Anesthesiology
    Dec 7, 2022

    Clinical Phenotypes in Pericarditis: IL-1RA Antibodies and suPAR

    Not yet recruiting
    • Pericarditis
    • IL1RA Antibody Assay
    • suPAR Testing
    • Homburg, Germany
    • +8 more
    Jun 22, 2023

    Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8

    Active, not recruiting
    Has Results
    • Anatomic Stage II Breast Cancer AJCC v8
    • +16 more
    • Durvalumab
    • Tremelimumab
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 18, 2022

    Solid Tumor, Adult, Lymphoma, EphA2 Overexpression Trial in Beijing (TP53-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

    Recruiting
    • Solid Tumor, Adult
    • +6 more
    • TP53-EphA-2-CAR-DC
    • +3 more
    • Beijing, Beijing, China
      Biotherapeutic Department of Chinsese PLA Gereral Hospital
    Nov 29, 2022

    Moderate Covid19 Trial in Riyadh (Leukotriene Receptor Antagonist, Placebo)

    Recruiting
    • Moderate Covid19
    • Leukotriene Receptor Antagonist
    • Placebo
    • Riyadh, Saudi Arabia
      King Abdulaziz Medical city, MNGHA
    May 5, 2021

    Recurrent Multiple Myeloma, Refractory Multiple Myeloma Trial in Los Angeles (procedure, drug, other)

    Not yet recruiting
    • Recurrent Multiple Myeloma
    • Refractory Multiple Myeloma
    • Bone Marrow Aspiration
    • +10 more
    • Los Angeles, California
      Melanie Ayala Ceja
    Jul 10, 2023

    Peptic Ulcer Trial in Kaohsiung (histamine-2 receptor antagonist, Placebo)

    Completed
    Has Results
    • Peptic Ulcer
    • histamine-2 receptor antagonist
    • Placebo
    • Kaohsiung, Taiwan
      Kaohsiung Veterans General Hospital
    Mar 8, 2019